Author details

Full Name

Hongchuan Li

Affiliation

Frederick National Laboratory for Cancer Research

ORCID

Career Start Year

2008

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37976160	Abundant binary promoter switches in lineage-determining transcription factors indicate a digital component of cell fate determination.	Cell Rep	2023
37801092	The KIR2DL1 intermediate upstream element participates in gene activation.	Immunogenetics	2023
36230818	HPV16 E7 Nucleotide Variants Found in Cancer-Free Subjects Affect E7 Protein Expression and Transformation.	Cancers (Basel)	2022
35858344	Genetic variation that determines <i>TAPBP</i> expression levels associates with the course of malaria in an HLA allotype-dependent manner.	Proc Natl Acad Sci U S A	2022
32784501	Genetic and Epigenetic Regulation of the Smoothened Gene (SMO) in Cancer Cells.	Cancers (Basel)	2020
31998314	Tuning of NK-Specific HLA-C Expression by Alternative mRNA Splicing.	Front Immunol	2020
31231651	The Human <i>TET2</i> Gene Contains Three Distinct Promoter Regions With Differing Tissue and Developmental Specificities.	Front Cell Dev Biol	2019
31471108	Differential Activation of the Transcription Factor IRF1Â Underlies the Distinct Immune Responses Elicited by Type I and Type III Interferons.	Immunity	2019
29329284	Identification of an elaborate NK-specific system regulating HLA-C expression.	PLoS Genet	2018
30270560	Identification of trophoblast-specific elements in the HLA-C core promoter.	HLA	2018
29559979	Association of <i>TNFRSF1B</i> Promoter Polymorphisms with Human Disease: Further Studies Examining T-Regulatory Cells Are Required.	Front Immunol	2018
27819678	TET2 binds the androgen receptor and loss is associated with prostate cancer.	Oncogene	2017
27467282	Analysis of Ly49 gene transcripts in mature NK cells supports a role for the Pro1 element in gene activation, not gene expression.	Genes Immun	2016
26656451	Characterization of KIR intermediate promoters reveals four promoter types associated with distinct expression patterns of KIR subtypes.	Genes Immun	2016
27817866	HLA-C Level Is Regulated by a Polymorphic Oct1 Binding Site in the HLA-C Promoter Region.	Am J Hum Genet	2016
28033606	Correction: Activating Receptor Signals Drive Receptor Diversity in Developing Natural Killer Cells.	PLoS Biol	2016
27500644	Activating Receptor Signals Drive Receptor Diversity in Developing Natural Killer Cells.	PLoS Biol	2016
24842371	Transcriptional regulation of Munc13-4 expression in cytotoxic lymphocytes is disrupted by an intronic mutation associated with a primary immunodeficiency.	J Exp Med	2014
25474109	Interleukin-1 and interferon-Î³ orchestrate Î²-glucan-activated human dendritic cell programming via IÎºB-Î¶ modulation.	PLoS One	2014
24989671	Characterization of a weakly expressed KIR2DL1 variant reveals a novel upstream promoter that controls KIR expression.	Genes Immun	2014
23675302	LAB/NTAL facilitates fungal/PAMP-induced IL-12 and IFN-Î³ production by repressing Î²-catenin activation in dendritic cells.	PLoS Pathog	2013
23863987	Identification of a KIR antisense lncRNA expressed by progenitor cells.	Genes Immun	2013
22570471	Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent manner.	J Biol Chem	2012
23552698	Genomic copy number alterations in clear cell renal carcinoma: associations with case characteristics and mechanisms of VHL gene inactivation.	Oncogenesis	2012
22661295	Promoter variants in the MSMB gene associated with prostate cancer regulate MSMB/NCOA4 fusion transcripts.	Hum Genet	2012
20033655	Identification and analysis of novel transcripts and promoters in the human killer cell immunoglobulin-like receptor (KIR) genes.	Methods Mol Biol	2010
18987359	The transcription factor c-Myc enhances KIR gene transcription through direct binding to an upstream distal promoter element.	Blood	2009
19383797	Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility.	Proc Natl Acad Sci U S A	2009
19008943	Genetic control of variegated KIR gene expression: polymorphisms of the bi-directional KIR3DL1 promoter are associated with distinct frequencies of gene expression.	PLoS Genet	2008

1 - 29 of 29

Steven Witte

University of Alabama at Birmingham

Career Start Year 2014

Number of shared co-authors 0

David Langlais

McGill University

Career Start Year 2008

Number of shared co-authors 0

Matthias Farlik

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences

Career Start Year 2007

Number of shared co-authors 0

Ansuman T Satpathy

Stanford University

Career Start Year 2005

Number of shared co-authors 0

Christopher Benner

Michigan State University College of Human Medicine

Career Start Year 2004

Number of shared co-authors 0

Shintaro Katayama

Folkhalsan Research Center

Career Start Year 2003

Number of shared co-authors 0

Tarjei S Mikkelsen

Harvard University, USA Broad Institute, USA Harvard Stem Cell Institute

Career Start Year 2001

Number of shared co-authors 0

Sophia Derdak

Medical University of Vienna

Career Start Year 2001

Number of shared co-authors 0

Peter White

The Ohio State University

Career Start Year 2000

Number of shared co-authors 0

Sven Heinz

U.C. San Diego School of Medicine

Career Start Year 2000

Number of shared co-authors 0

Ru-Fang Yeh

Genentech Inc.

Career Start Year 1999

Number of shared co-authors 0

Alexandre Montpetit

McGill University and Genome Quebec Innovation Centre

Career Start Year 1998

Number of shared co-authors 2

Martin Hirst

University of British Columbia

Career Start Year 1998

Number of shared co-authors 0

Adrian M St??tz

St. Anna Children's Cancer Research Institute (CCRI)

Career Start Year 1997

Number of shared co-authors 0

Michael Rehli

University Hospital Regensburg

Career Start Year 1995

Number of shared co-authors 0

Thomas J Hudson

Ontario Institute for Cancer Research

Career Start Year 1991

Number of shared co-authors 7

Sean M Grimmond

The University of Melbourne

Career Start Year 1990

Number of shared co-authors 0

Naganari Ohkura

Graduate School of Medicine, Osaka University

Career Start Year 1989

Number of shared co-authors 0

Geoffrey Neale

St. Jude Children's Research Hospital

Career Start Year 1989

Number of shared co-authors 5

Christine A Wells

The University of Melbourne

Career Start Year 1989

Number of shared co-authors 0

Nir Hacohen

Broad Institute of MIT and Harvard

Career Start Year 1989

Number of shared co-authors 1

Jiannis Ragoussis

McGill University

Career Start Year 1986

Number of shared co-authors 0

Stephan Beck

UCL Cancer Institute, University College London

Career Start Year 1983

Number of shared co-authors 2

Anjana Rao

La Jolla Institute for Immunology

Career Start Year 1983

Number of shared co-authors 0

Jeremy M Boss

Emory University School of Medicine

Career Start Year 1976

Number of shared co-authors 0

Bruce J Aronow

Cincinnati Children's Hospital Medical Center

Career Start Year 1975

Number of shared co-authors 0

Daniel G Tenen

Harvard Stem Cell Institute, Harvard Medical School

Career Start Year 1975

Number of shared co-authors 0

Louise C Showe

The Wistar Institute

Career Start Year 1975

Number of shared co-authors 1

Sean Davis

Johns Hopkins School of Medicine, National Cancer Institute, Princeton University, University of Colorado Anschutz Medical Campus, University of Pittsburgh, University of Washington

Career Start Year 1974

Number of shared co-authors 15

Tak W Mak

Princess Margaret Cancer Centre, University Health Network

Career Start Year 1970

Number of shared co-authors 0

row(s) 1 - 30 of 30